Vladimir Vonka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vladimir Vonka has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
E Hamsíková
4 shared publications- Eva Hamsikova
Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
2 shared publications - F. X. Bosch
Servicio de Epidemiología y Registro del Cáncer, Institut Català d'Oncología, L'Hospitalet, Barcelona
2 shared publications R Vonka
2 shared publicationsV Hofmannová
2 shared publicationsA Beková
1 shared publication
Latest Publications
- 7 July 2011
- Published by Springer Nature
- p. 7-17
Gene Therapy: Hopes and Problems
- 1 July 2010
- Vol. 56 (7) , 739-46
[Will vaccines appear on the scene of oncology in the near future?].
In parallel with the increasing knowledge of the role played by the immune system in the control oftumourgrowth, the efforts to develop anti-cancer vaccines intensify. In the present time two highly efficient prophylactic vaccines against the virus-induced cancers are in use, but a rapid progress in the development of anti-cancer therapeutic vaccines can also be seen. It is conditioned by an increasing understanding of the biology of the tumor cells and the rapid progress in the field of immunology. Nevertheless, these developments are associated with a number of difficulties, among which the immunosuppressive activities of the tumor cells and the tumor microenvironment are the most important. On the example of chronic myeloid leukemia the author proposes a strategy for the development ofa therapeutic cancer vaccine.
- 1 July 2010
- Vol. 56 (7) , 739-46
[Will vaccines appear on the scene of oncology in the near future?].
In parallel with the increasing knowledge of the role played by the immune system in the control oftumourgrowth, the efforts to develop anti-cancer vaccines intensify. In the present time two highly efficient prophylactic vaccines against the virus-induced cancers are in use, but a rapid progress in the development of anti-cancer therapeutic vaccines can also be seen. It is conditioned by an increasing understanding of the biology of the tumor cells and the rapid progress in the field of immunology. Nevertheless, these developments are associated with a number of difficulties, among which the immunosuppressive activities of the tumor cells and the tumor microenvironment are the most important. On the example of chronic myeloid leukemia the author proposes a strategy for the development ofa therapeutic cancer vaccine.
- 11 February 2009
- Published by Spandidos Publications in Oncology Reports
- Vol. 21 (3) , 793-799
Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells
For our experiments we selected two oncogenic, bcr-abl-transformed mouse cell lines, viz. B210 and 12B1. Both cell types are capable of inducing leukemia-like disease in syngeneic BALB/c mice after intravenous inoculation. 12B1 cells can moreover form solid tumors after subcutaneous injection. Since immunotherapy would expectedly be most effective in animals in which the tumor mass had been reduced by other therapeutic means, we attempted to develop a combined therapeutic system for suppressing tumor growth. In the present study, mice inoculated with the aggressive 12B1 cells were treated with imatinib mesylate (IM), mouse interferon α (IFNα) and cyclophosphamide (Cy) in combination with genetically modified tumor cells engineered to produce various cytokines. These cell vaccines had been derived from B210 cells. Therapy with IM or IFNα alone or cell immunotherapy alone resulted in partial suppression of tumor growth. Of the different therapeutic regimens tested, a combination of repeated doses of IM, IFNα and cell vaccines with one relatively high dose of Cy (200 mg/kg) was the most effective, resulting in tumor-free survival of a large portion of mice. The spleens, livers and bone marrows of the successfully treated animals were tested for the presence of bcr-abl-positive cells by means of RT-PCR technique. Results were negative, this suggesting that the animals had been cleared of residual disease.
- 11 February 2009
- Published by Spandidos Publications in Oncology Reports
- Vol. 21 (3) , 793-799
Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells
For our experiments we selected two oncogenic, bcr-abl-transformed mouse cell lines, viz. B210 and 12B1. Both cell types are capable of inducing leukemia-like disease in syngeneic BALB/c mice after intravenous inoculation. 12B1 cells can moreover form solid tumors after subcutaneous injection. Since immunotherapy would expectedly be most effective in animals in which the tumor mass had been reduced by other therapeutic means, we attempted to develop a combined therapeutic system for suppressing tumor growth. In the present study, mice inoculated with the aggressive 12B1 cells were treated with imatinib mesylate (IM), mouse interferon α (IFNα) and cyclophosphamide (Cy) in combination with genetically modified tumor cells engineered to produce various cytokines. These cell vaccines had been derived from B210 cells. Therapy with IM or IFNα alone or cell immunotherapy alone resulted in partial suppression of tumor growth. Of the different therapeutic regimens tested, a combination of repeated doses of IM, IFNα and cell vaccines with one relatively high dose of Cy (200 mg/kg) was the most effective, resulting in tumor-free survival of a large portion of mice. The spleens, livers and bone marrows of the successfully treated animals were tested for the presence of bcr-abl-positive cells by means of RT-PCR technique. Results were negative, this suggesting that the animals had been cleared of residual disease.
- Open Access
- 1 December 2007
- Published by National Institute of Public Health, Prague in Central European Journal of Public Health
- Vol. 15 (4) , 131-139
Vaccines against Human Papillomaviruses - A Major Breakthrough in Cancer Prevention
Carcinoma of the cervix (CaCer) is the second most frequent malignancy in women on a global scale. Epidemiological studies carried out at the beginning of the second half of the 20th century showed that CaCer was of infectious nature and that ...
- 1 December 2007
- Published by National Institute of Public Health, Prague in Central European Journal of Public Health
- Vol. 15 (4) , 131-139
Open AccessVaccines against Human Papillomaviruses - A Major Breakthrough in Cancer Prevention
Carcinoma of the cervix (CaCer) is the second most frequent malignancy in women on a global scale. Epidemiological studies carried out at the beginning of the second half of the 20th century showed that CaCer was of infectious nature and that ...
- 1 April 2007
- Vol. 56 (2) , 94-8
[Resolution of the HPV Vaccine Working Group of December 12, 2006].
- 1 January 2006
- Vol. 145 (7) , 511-21
[Cervical cancer uteri: from the etiology to prophylactic vaccine].
The authors briefly summarize the history of the research on the cervical cancer (CC) which has resulted in the recognition of human papillomaviruses (HPV) as the key etiological factors in CC. They describe the HPV properties and the process leading to the development of prophylactic vaccines directed against HPV genotypes most frequently responsible for the development of CC. They summarize the results of the recent studies with these vaccines and strongly recommend their introduction. At the same time they stress that the vaccination programs must not disturb the present system of preventive gynecological check-ups. These will remain the most efficient weapon in the war against CC for at least two decades.
- 1 January 2006
- Vol. 145 (7) , 511-21
[Cervical cancer uteri: from the etiology to prophylactic vaccine].
The authors briefly summarize the history of the research on the cervical cancer (CC) which has resulted in the recognition of human papillomaviruses (HPV) as the key etiological factors in CC. They describe the HPV properties and the process leading to the development of prophylactic vaccines directed against HPV genotypes most frequently responsible for the development of CC. They summarize the results of the recent studies with these vaccines and strongly recommend their introduction. At the same time they stress that the vaccination programs must not disturb the present system of preventive gynecological check-ups. These will remain the most efficient weapon in the war against CC for at least two decades.
- Open Access
- 1 January 2005
- Published by Charles University in Prague, Karolinum Press in Folia Biologica
- Vol. 51 (1) , 12-18
Characteristic of Two Mouse bcr-abl-Transformed Cell Lines: I. General Properties of the Cells
In an effort to develop an experimental system suitable for immunological studies in which BcrAbl-positive cells are to be used as antigens, we examined the properties of two mouse (Balb/c) established cell lines that express the Bcr-Abl protein and are oncogenic for syngeneic animals. Under standard conditions the two cell lines, viz. Ba-p210 (B210) and 12B1, expressed comparable amounts of the Bcr-Abl protein. However, they differed in a number of characteristics. From the morphological point of view, B210 cells were the more homogeneous, being mainly represented by leukaemic blastic cells with a large number of AgNORs as markers indicating a high proliferative activity. 12B1 cells were more polymorphic and giant cells were detected within their populations. Many 12B1 cells exhibited nuclear segmentation and “band-like“ structures. Markers of proliferation were less frequent in 12B1 and the tendency for aging was more pronounced in these cells. The 12B1 cells were slightly more sensitive to imatinib mesylate than B210 cells. In B210 cells, the expression of MHC class I was downregulated, which was not the case with 12B1 cells. Both cell lines induced leukaemia-like disease in mice after intravenous application but, as compared with B210, 12B1 cells were about 100 times more oncogenic and the disease they induced was more aggressive. Moreover, 12B1, but not B210, induced tumours after subcutaneous or intraperitoneal inoculation.
- 1 January 2005
- Published by Charles University in Prague, Karolinum Press in Folia Biologica
- Vol. 51 (1) , 12-18
Open AccessCharacteristic of Two Mouse bcr-abl-Transformed Cell Lines: I. General Properties of the Cells
In an effort to develop an experimental system suitable for immunological studies in which BcrAbl-positive cells are to be used as antigens, we examined the properties of two mouse (Balb/c) established cell lines that express the Bcr-Abl protein and are oncogenic for syngeneic animals. Under standard conditions the two cell lines, viz. Ba-p210 (B210) and 12B1, expressed comparable amounts of the Bcr-Abl protein. However, they differed in a number of characteristics. From the morphological point of view, B210 cells were the more homogeneous, being mainly represented by leukaemic blastic cells with a large number of AgNORs as markers indicating a high proliferative activity. 12B1 cells were more polymorphic and giant cells were detected within their populations. Many 12B1 cells exhibited nuclear segmentation and “band-like“ structures. Markers of proliferation were less frequent in 12B1 and the tendency for aging was more pronounced in these cells. The 12B1 cells were slightly more sensitive to imatinib mesylate than B210 cells. In B210 cells, the expression of MHC class I was downregulated, which was not the case with 12B1 cells. Both cell lines induced leukaemia-like disease in mice after intravenous application but, as compared with B210, 12B1 cells were about 100 times more oncogenic and the disease they induced was more aggressive. Moreover, 12B1, but not B210, induced tumours after subcutaneous or intraperitoneal inoculation.
- 1 January 1999
- Vol. 45 (1) , 31-4
The frequency of HLA-DRB1 and -DQB1 alleles in cervical cancer cases in the Czech Republic.
The distribution of HLA class II DRB1 and DQB1 alleles in cervical carcinoma patients was compared with the frequency of these alleles found in healthy population living in the Czech Republic. The RFLP analysis and PCR-SSP were used for DNA typing. Although the differences in the frequency of DRB1*03, DQB1*02 and DQB1*0303 alleles between the cases and the controls were rather large, corrected P values did not reach significance.
- 1 January 1999
- Vol. 45 (1) , 31-4
The frequency of HLA-DRB1 and -DQB1 alleles in cervical cancer cases in the Czech Republic.
The distribution of HLA class II DRB1 and DQB1 alleles in cervical carcinoma patients was compared with the frequency of these alleles found in healthy population living in the Czech Republic. The RFLP analysis and PCR-SSP were used for DNA typing. Although the differences in the frequency of DRB1*03, DQB1*02 and DQB1*0303 alleles between the cases and the controls were rather large, corrected P values did not reach significance.
- 1 November 1998
- Vol. 34 (4) , 142-8
[Inflammatory stromal reaction in epithelial neoplasia of the uterine cervix in correlation with HPV infection].
260 cases of women with epithelial neoplasias of the uterine cervix were studied: HPV infection was detected by DNA in situ hybridization and serology, simultaneously structure and intensity of stromal inflammatory reaction (SR) were evaluated (semiquantitatively) as well as standard clinical immunological parametres investigated by serology. Results proved the same character of SR in intraepithelial lesions and invasive carcinomas and the intensity of SR increasing in relation to the gravity of epithelial dysplasia. There was not found any significant difference in SR between cases with detected HPV infection and cases lacking it. Summarized immunological parametres were in limits of normal reference range.
- 1 November 1998
- Vol. 34 (4) , 142-8
[Inflammatory stromal reaction in epithelial neoplasia of the uterine cervix in correlation with HPV infection].
260 cases of women with epithelial neoplasias of the uterine cervix were studied: HPV infection was detected by DNA in situ hybridization and serology, simultaneously structure and intensity of stromal inflammatory reaction (SR) were evaluated (semiquantitatively) as well as standard clinical immunological parametres investigated by serology. Results proved the same character of SR in intraepithelial lesions and invasive carcinomas and the intensity of SR increasing in relation to the gravity of epithelial dysplasia. There was not found any significant difference in SR between cases with detected HPV infection and cases lacking it. Summarized immunological parametres were in limits of normal reference range.
- 1 February 1997
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 15 (2) , 610-619
Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer.
PURPOSE To assess whether human papillomavirus (HPV) DNA detection in cervical cancer specimens, or antibodies to selected HPV 16 peptides are predictors of tumor recurrence and long-term survival in patients with squamous cell invasive cervical cancer. SUBJECTS AND METHODS Four hundred seventy-one cases included in two population-based case-control studies underwent follow-up evaluation. The survival and cause of death were ascertained for 410 cases (87%), with a median follow-up time of 4.6 years after diagnosis. HPV DNA was assessed using an L1 polymerase chain reaction (PCR)-based system and Southern hybridization (SH) on scraped cytologic specimens or biopsies. HPV 16 antibodies to E2, L2, and E7 peptides were detected with enzyme-linked immunosorbent assay (ELISA). RESULTS Clinical stage was the only independent prognostic factor for recurrence or survival. Although seropositivity to HPV 16 E7/3 peptide predicted a twofold excess risk of mortality (adjusted hazards ratio [HRa] = 2.0; 95% confidence interval [CI], 1.2 to 3.3), the association was restricted to stage I (HRa = 6.6; 95% CI, 1.2 to 37.6) and II (HRa = 5.9; 95% CI, 2.1 to 16.5) patients. The presence of HPV DNA (HRa = 0.9; 95% CI, 0.5 to 1.5), different estimates of the HPV viral load and the HPV type identified were not predictors of tumor recurrence or survival. CONCLUSION The presence of antibodies to HPV 16 E7 proteins is of prognostic value in early-stage cervical cancer. Our results provide strong evidence that detection and typing of HPV DNA in cervical cells or tissues is not a prognostic factor for recurrence or survival.
- 1 February 1997
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 15 (2) , 610-619
Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer.
PURPOSE To assess whether human papillomavirus (HPV) DNA detection in cervical cancer specimens, or antibodies to selected HPV 16 peptides are predictors of tumor recurrence and long-term survival in patients with squamous cell invasive cervical cancer. SUBJECTS AND METHODS Four hundred seventy-one cases included in two population-based case-control studies underwent follow-up evaluation. The survival and cause of death were ascertained for 410 cases (87%), with a median follow-up time of 4.6 years after diagnosis. HPV DNA was assessed using an L1 polymerase chain reaction (PCR)-based system and Southern hybridization (SH) on scraped cytologic specimens or biopsies. HPV 16 antibodies to E2, L2, and E7 peptides were detected with enzyme-linked immunosorbent assay (ELISA). RESULTS Clinical stage was the only independent prognostic factor for recurrence or survival. Although seropositivity to HPV 16 E7/3 peptide predicted a twofold excess risk of mortality (adjusted hazards ratio [HRa] = 2.0; 95% confidence interval [CI], 1.2 to 3.3), the association was restricted to stage I (HRa = 6.6; 95% CI, 1.2 to 37.6) and II (HRa = 5.9; 95% CI, 2.1 to 16.5) patients. The presence of HPV DNA (HRa = 0.9; 95% CI, 0.5 to 1.5), different estimates of the HPV viral load and the HPV type identified were not predictors of tumor recurrence or survival. CONCLUSION The presence of antibodies to HPV 16 E7 proteins is of prognostic value in early-stage cervical cancer. Our results provide strong evidence that detection and typing of HPV DNA in cervical cells or tissues is not a prognostic factor for recurrence or survival.